Successful interferon alpha therapy in atopic dermatitis of Besnier's prurigo pattern with normal serum IgE and blood eosinophil fraction: randomized case-controlled study.
A randomized case-controlled study was carried out to investigate for interferon alpha therapy in atopic dermatitis (AD) of Besnier's prurigo pattern with normal serum IgE and normal blood eosinophil fraction. Interferon alpha therapy was conducted on 14 non-responders to interferon gamma and subsequent thymopentin therapy among 100 atopic dermatitis patients. Eight patients who improved significantly, showed skin lesions of the Besnier's prurigo pattern with normal serum IgE and normal blood eosinophil fraction. For the randomized prospective case-controlled study, 44 patients with the above characteristics were selected. Thirteen Besnier's prurigo patients were treated with interferon alpha therapy, ten with interferon gamma, ten with thymopentin, and the remaining 11 were untreated as the control group. With interferon alpha therapy, 11 out of 13 Besnier's prurigo patients with normal IgE and normal blood eosinophil fraction improved significantly, two out of ten improved with interferon gamma therapy, and none improved with thymopentin therapy or in the untreated control group. Interferon alpha therapy was effective on AD of Besnier's prurigo pattern with normal serum IgE and normal blood eosinophil fraction. These results suggest the possibility of non-IgE-mediated AD and the heterogeneity of atopic dermatitis.
Noh
G
G
Department of Pediatrics, Sungkyunkwan University, School of Medicine, Seoul, Korea.
Lee
K Y
KY
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000328:Adult; D016022:Case-Control Studies; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D004804:Eosinophils / Q000378:metabolism*; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood*; D007155:Immunologic Factors / Q000627:therapeutic use; D016898:Interferon-alpha / Q000627:therapeutic use*; D007371:Interferon-gamma / Q000627:therapeutic use; D008297:Male; D011446:Prospective Studies; D011536:Prurigo / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000378:metabolism; D016305:Thymopentin / Q000627:therapeutic use; D013997:Time Factors
D000276:Adjuvants, Immunologic; D007155:Immunologic Factors; D016898:Interferon-alpha; D011994:Recombinant Proteins; D007073:Immunoglobulin E; D007371:Interferon-gamma; D016305:Thymopentin